IRVINE, Calif., Jan. 31, 2011 /PRNewswire/ — Endologix, Inc.
(Nasdaq:
ELGX), developer of minimally invasive treatments for aortic
disorders, announced today the publication of favorable clinical
results for the Nellix technology for the endovascular repair of
abdominal aortic aneurysm (EVAR). The peer-reviewed article
reported initial results from the international multicenter
clinical trial, with successful aneurysm exclusion in all patients,
and no late aneurysm or device-related adverse events or secondary
procedures.
Lead author and scientific advisor Carlos E. Donayre, MD
(Harbor-UCLA Medical Center, Torrance, CA) commented, “The Nellix
technology was designed to address the limitations of currently
available EVAR devices and to expand the therapy to more patients.
By filling the aneurysm sac, the Nellix device may reduce the
incidence of endoleaks, secondary interventions and the need for
annual CT scan follow-up. We are encouraged by these
promising results, and look forward to the availability of broader
experience in the near future.”
The publication, entitled “Initial clinical experience with a
sac anchoring endoprosthesis for aortic aneurysm repair,” was
published in the February issue of the Journal of Vascular Surgery
(JVS). The study examined the initial and one year outcomes
of 21 patients treated at four international centers. An
independent core laboratory analyzed preoperative and
post-procedural computed tomography scans to determine aneurysm
exclusion and device stability over time.
John McDermott, President and Chief Executive Officer said, “We
believe the Nellix technology represents the next generation in
endovascular repair of abdominal aortic aneurysms. Since
completing the acquisition in December 2010, we are delighted that
initial results of the international trial are now published by a
peer revie
‘/>”/>
